EPCM
ALXN

Eton Park Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Eton Park Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-202,000
Closed -$24.7M – 48
2016
Q4 		$24.7M Buy
+202,000
New +$24.7M 0.49% 40
2013
Q4 		– Sell
-300,000
Closed -$34.8M – 61
2013
Q3 		$34.8M Buy
+300,000
New +$32.9M 0.77% 30

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Eton Park Capital Management's ALXN Position: Q1 2017 in Review

Eton Park Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 202,000 shares — an estimated $24.7M sold.

Eton Park Capital Management first reported a position in ALXN in Q3 2013 and held it in 2 quarters. The position peaked at $34.8M in Q3 2013. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Eton Park Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Eton Park Capital Management sold 202,000 Alexion Pharmaceuticals shares in Q1 2017, an estimated $24.7M.
  • Eton Park Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Eton Park Capital Management's Alexion Pharmaceuticals position peaked at $34.8M in Q3 2013.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Eton Park Capital Management's 13F filing for Q1 2017, filed 15 May 2017.